LQDA
Liquidia Corp
$
26.090
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
26.160
Open
25.470
VWAP
25.46
Vol
1.82M
Mkt Cap
2.27B
Low
24.945
Amount
46.45M
EV/EBITDA(TTM)
--
Total Shares
76.38M
EV
2.26B
EV/OCF(TTM)
--
P/S(TTM)
31.60
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
100.20M
+1033.87%
0.330
-167.35%
72.93M
+2237.61%
0.080
-117.78%
94.30M
+3132.73%
-0.172
-61.73%
Estimates Revision
The market is revising Upward the revenue expectations for Liquidia Corporation (LQDA) for FY2025, with the revenue forecasts being adjusted by 84.11% over the past three months. During the same period, the stock price has changed by 27.58%.
Revenue Estimates for FY2025
Revise Upward
+84.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.42%
In Past 3 Month
Stock Price
Go Up
+27.58%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is 40.75 USD with a low forecast of 31.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.090
Low
31.00
Averages
40.75
High
54.00
Current: 26.090
Low
31.00
Averages
40.75
High
54.00
H.C. Wainwright
Buy
maintain
$35 -> $50
2025-11-04
New
Reason
H.C. Wainwright
Price Target
$35 -> $50
2025-11-04
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Liquidia to $50 from $35 and keeps a Buy rating on the shares. The firm says the company's profitability "arrived early" with Liquidia reporting "impressive" Q3 earnings. The investment story "has shifted from a binary launch to a profit driven story," the analyst tells investors in a research note.
Raymond James
Strong Buy
maintain
$41 -> $47
2025-11-04
New
Reason
Raymond James
Price Target
$41 -> $47
2025-11-04
New
maintain
Strong Buy
Reason
Raymond James raised the firm's price target on Liquidia to $47 from $41 and keeps a Strong Buy rating on the shares. Liquidia's Q3 earnings were driven by strong Yutrepia performance in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with net sales of $51.7M, over triple consensus estimates, and profitability achieved ahead of schedule, the analyst tells investors in a research note. Yutrepia accounted for roughly 75% of revenue growth in its market, aided by major PBM contracts and easing new-patient restrictions. Unadjusted peak sales estimates have been raised to about $2B from $1.1B, reflecting exceptional early launch momentum.
BofA
Buy
maintain
$37 -> $39
2025-11-03
New
Reason
BofA
Price Target
$37 -> $39
2025-11-03
New
maintain
Buy
Reason
BofA raised the firm's price target on Liquidia to $39 from $37 and keeps a Buy rating on the shares after the company reported Q3 net sales that beat BofA and the Street's sales forecasts. The firm believes shares are flat given the overhang on pending patent litigation that risks narrowing Yutrepia's indication statement, but it thinks today's results confirm Yutrepia's value proposition in the pulmonary hypertension market, a faster ramp to peak sales and much greater revenue opportunity from the PAH indication, the analyst tells investors.
Jefferies
Buy
maintain
$43 -> $45
2025-11-03
New
Reason
Jefferies
Price Target
$43 -> $45
2025-11-03
New
maintain
Buy
Reason
Jefferies raised the firm's price target on Liquidia to $45 from $43 and keeps a Buy rating on the shares following a strong Q3 that beat consensus and the firm's "bullish" expectations. Liquidia also hit operating profitability in Q3, two quarter's ahead of management's expectations and one quarter ahead of the firm's "already bullish estimates," the analyst added.
Jefferies
NULL
to
Buy
initiated
$31 -> $43
2025-08-15
Reason
Jefferies
Price Target
$31 -> $43
2025-08-15
initiated
NULL
to
Buy
Reason
Jefferies assumed coverage of Liquidia (LQDA) with a Buy rating and a price target of $43, up from $31. The firm expects Yutrepia to beat FY25 estimates and for the company to hit profitability in Q4 of 2025, adding that it views it as "highly unlikely" Yutrepia is pulled off the market due to United Therapeutics' (UTHR) patent litigation.
BofA
Buy
upgrade
$23 -> $35
2025-08-12
Reason
BofA
Price Target
$23 -> $35
2025-08-12
upgrade
Buy
Reason
BofA raised the firm's price target on Liquidia to $35 from $23 and keeps a Buy rating on the shares. The company reported solid 2Q results with an inventory stocking-driven sales beat, but more importantly, the management disclosed strong lead indicators for the Yutrepia launch that included over 550 new Yutrepia patient starts and over 900 unique prescription referrals, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Liquidia Corp (LQDA.O) is 31.50, compared to its 5-year average forward P/E of -13.09. For a more detailed relative valuation and DCF analysis to assess Liquidia Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-13.09
Current PE
31.50
Overvalued PE
9.50
Undervalued PE
-35.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-7.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.50
Undervalued EV/EBITDA
-15.85
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
23.67
Current PS
25.60
Overvalued PS
38.33
Undervalued PS
9.01
Financials
Annual
Quarterly
FY2025Q3
YoY :
+1121.72%
54.34M
Total Revenue
FY2025Q3
YoY :
-106.05%
1.77M
Operating Profit
FY2025Q3
YoY :
-84.74%
-3.53M
Net Income after Tax
FY2025Q3
YoY :
-86.67%
-0.04
EPS - Diluted
FY2025Q3
YoY :
-60.19%
-10.68M
Free Cash Flow
FY2025Q3
YoY :
+45.26%
94.16
Gross Profit Margin - %
FY2025Q3
YoY :
-73.70%
-155.79
FCF Margin - %
FY2025Q3
YoY :
-98.75%
-6.50
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.2M
USD
18
3-6
Months
14.5M
USD
31
6-9
Months
570.4K
USD
10
0-12
Months
1.0M
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.2M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
3
1.1M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.2M
USD
18
3-6
Months
14.5M
USD
31
6-9
Months
570.4K
USD
10
0-12
Months
1.0M
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LQDA News & Events
Events Timeline
2025-11-03 (ET)
2025-11-03
06:38:44
Liquidia announces Q3 earnings per share of 4 cents, falling short of consensus estimate of 33 cents.
2025-10-07 (ET)
2025-10-07
10:25:00
BTIG Biotech Analyst Hosts Conference Call for Analysts and Industry Professionals
2025-10-07
04:55:00
BTIG Biotech Analyst Hosts Conference Call for Analysts and Industry Experts
Sign Up For More Events
Sign Up For More Events
News
2.0
11-04BenzingaMajor Stocks on the Rise Tuesday: Henry Schein, Sanmina, Wingstop, Waters, and More
4.0
11-04BenzingaAnalyst Perspectives: Liquidia as Viewed by Seven Experts
4.0
11-04BenzingaNeedham Keeps Buy Rating on Liquidia and Increases Price Target to $52
Sign Up For More News
People Also Watch
EMBC
Embecta Corp
13.790
USD
+2.45%
BOW
Bowhead Specialty Holdings Inc
25.870
USD
+3.19%
IGIC
International General Insurance Holdings Ltd
21.930
USD
-1.66%
LPG
Dorian LPG Ltd
27.790
USD
+2.28%
SII
Sprott Inc
90.120
USD
+7.11%
IRS
IRSA Inversiones y Representaciones SA
14.990
USD
+3.74%
ARRY
Array Technologies Inc
8.540
USD
+2.03%
PLSE
Pulse Biosciences Inc
15.460
USD
-1.72%
PDFS
PDF Solutions Inc
26.450
USD
-3.78%
FAQ
What is Liquidia Corp (LQDA) stock price today?
The current price of LQDA is 26.09 USD — it has increased 1.91 % in the last trading day.
What is Liquidia Corp (LQDA)'s business?
What is the price predicton of LQDA Stock?
What is Liquidia Corp (LQDA)'s revenue for the last quarter?
What is Liquidia Corp (LQDA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Liquidia Corp (LQDA)'s fundamentals?
How many employees does Liquidia Corp (LQDA). have?